Related Experiment Video
Updated: May 23, 2026

A Standardized Procedure of Dressing Management for Toxic Epidermal Necrolysis
Published on: March 14, 2025
Advances in the management of cutaneous toxicities of targeted therapies
Caroline Robert1, Vincent Sibaud, Christine Mateus
1Institute Gustave Roussy, Villejuif, France. caroline.robert@igr.fr
Abstract:
Contrary to what might have been expected, the effects of targeted therapies are not limited to the cancer cells and are unfortunately associated with many and numerous adverse events. Dermatologic manifestations are among the most frequently observed, and, when severe and/or protracted, they inevitably impact the quality of life of patients. Management of these various side effects is empirical and mostly based on expert advice and consensus. We will review the skin side effects of EGFR, VEGFR, KIT, platelet-derived growth factor receptor (PDGFR), and BCR-ABL inhibitors, as well as mTOR inhibitors.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Skin Cancer
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Modified-Release Drug Delivery Systems: Site-Targeted
Drug Toxicity: Allergic Reactions
